Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Nov;18(5):693–700. doi: 10.1111/j.1365-2125.1984.tb02531.x

Azathioprine metabolism in kidney transplant recipients.

L Lennard, C B Brown, M Fox, J L Maddocks
PMCID: PMC1463549  PMID: 6391532

Abstract

Azathioprine metabolite concentrations were studied in 54 kidney transplant recipients. Thirty-seven of these patients were studied over a 6 month period to investigate the intrapatient variation in metabolite concentrations. All patients had stable functioning grafts and normal peripheral white blood cell counts. The metabolites measured were plasma 6-mercaptopurine and red blood cell 6-thioguanine nucleotide. There was no correlation between azathioprine dose and plasma 6-mercaptopurine concentration but there was a significant correlation between dose and red blood cell 6-thioguanine nucleotide concentration (rs = 0.41, P less than 0.005). The individual transplant recipient showed little variation in metabolite concentrations over several months. Using this group as a control we studied metabolite concentrations in patients with kidney transplants who developed leucopenia. Our preliminary findings indicate that elevated red cell 6-thioguanine nucleotide concentrations, above the control range, can be associated with bone marrow depression.

Full text

PDF
693

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Safi S. A., Maddocks J. L. Azathioprine and 6-mercaptopurine (6-MP) suppress the human mixed lymphocyte reaction (MLR) by different mechanisms. Br J Clin Pharmacol. 1984 Apr;17(4):417–422. doi: 10.1111/j.1365-2125.1984.tb02366.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Al-Safi S. A., Maddocks J. L. Effects of azathioprine on the human mixed lymphocyte reaction (MLR). Br J Clin Pharmacol. 1983 Feb;15(2):203–209. doi: 10.1111/j.1365-2125.1983.tb01487.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BROCKMAN R. W. BIOCHEMICAL ASPECTS OF MERCAPTOPURINE INHBITION AND RESISTANCE. Cancer Res. 1963 Sep;23:1191–1201. [PubMed] [Google Scholar]
  4. Ding T. L., Benet L. Z. Determination of 6-mercaptopurine and azathioprine in plasma by high-performance liquid chromatography. J Chromatogr. 1979 Jul 21;163(3):281–288. doi: 10.1016/s0378-4347(00)81415-2. [DOI] [PubMed] [Google Scholar]
  5. ELION G. B., CALLAHAN S., RUNDLES R. W., HITCHINGS G. H. RELATIONSHIP BETWEEN METABOLIC FATES AND ANTITUMOR ACTIVITIES OF THIOPURINES. Cancer Res. 1963 Sep;23:1207–1217. [PubMed] [Google Scholar]
  6. Haesslein H. C., Pierce J. C., Lee H. M., Hume D. M. Leukopenia and azathioprine management in renal homotransplantation. Surgery. 1972 Apr;71(4):598–604. [PubMed] [Google Scholar]
  7. Jonkers R. E., Oosterhuis B., ten Berge R. J., van Boxtel C. J. Analysis of 6-mercaptopurine in human plasma with a high-performance liquid chromatographic method including post-column derivatization and fluorimetric detection. J Chromatogr. 1982 Dec 10;233:249–255. doi: 10.1016/s0378-4347(00)81751-x. [DOI] [PubMed] [Google Scholar]
  8. Kelley W. N., Rosenbloom F. M., Seegmiller J. E. The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism. J Clin Invest. 1967 Sep;46(9):1518–1529. doi: 10.1172/JCI105643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lennard L., Maddocks J. L. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J Pharm Pharmacol. 1983 Jan;35(1):15–18. doi: 10.1111/j.2042-7158.1983.tb04255.x. [DOI] [PubMed] [Google Scholar]
  10. Lennard L., Murphy M. F., Maddocks J. L. Severe megaloblastic anaemia associated with abnormal azathioprine metabolism. Br J Clin Pharmacol. 1984 Feb;17(2):171–172. doi: 10.1111/j.1365-2125.1984.tb02333.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lennard L., Rees C. A., Lilleyman J. S., Maddocks J. L. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983 Oct;16(4):359–363. doi: 10.1111/j.1365-2125.1983.tb02178.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lin S. N., Jessup K., Floyd M., Wang T. P., van Buren C. T., Caprioli R. M., Kahan B. D. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients. Transplantation. 1980 Apr;29(4):290–294. doi: 10.1097/00007890-198004000-00006. [DOI] [PubMed] [Google Scholar]
  13. Maddocks J. L. Assay of azathioprine, 6-mercaptopurine and a novel thiopurine metabolite in human plasma. Br J Clin Pharmacol. 1979 Sep;8(3):273–278. doi: 10.1111/j.1365-2125.1979.tb01014.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Morgan E. J. The Distribution of Xanthine Oxidase I. Biochem J. 1926;20(6):1282–1291. doi: 10.1042/bj0201282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Swanson M. A., Schwartz R. S. Immunosuppressive therapy. The relation between clinical response and immunologic competence. N Engl J Med. 1967 Jul 27;277(4):163–170. doi: 10.1056/NEJM196707272770401. [DOI] [PubMed] [Google Scholar]
  16. Tidd D. M., Paterson A. R. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974 Apr;34(4):738–746. [PubMed] [Google Scholar]
  17. Zimm S., Collins J. M., O'Neill D., Chabner B. A., Poplack D. G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983 Dec;34(6):810–817. doi: 10.1038/clpt.1983.254. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES